AID Contributes to Accelerated Disease Progression in the TCL1 Mouse Transplant Model for CLL.

ABSTRACT: Adaptive somatic mutations conferring treatment resistance and accelerated disease progression is still a major problem in cancer therapy. Additionally in CLL, patients receiving novel, efficient drugs frequently become treatment refractory and eventually relapse. Activation-induced deaminase (AID) is a cytosine deaminase that catalyzes somatic hypermutation of genomic DNA at the immunoglobulin locus in activated B cells. As considerable off-target mutations by AID have been discerned in chronic lymphocytic leukemia, it is essential to investigate to which extent these mutations contribute to disease progression to estimate whether AID inhibition could counteract drug resistance mechanisms. In this study, we examined the TCL1 mouse model for CLL on an AID pro- and deficient background by c

SUBMITTER: Schubert M 

PROVIDER: S-EPMC8198502 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature